Helicobacter pylori remains common, often silent, and clinically consequential
Helicobacter pylori infection sits in an awkward place in everyday practice: it is usually asymptomatic, yet it is tied to upper gastrointestinal disease and, rarely, gastric cancer. Every infected patient develops histological gastritis, but the clinical expression ranges from no symptoms at all to dyspepsia, peptic ulcer disease, and long-term mucosal injury. In primary care, that variability creates a familiar diagnostic problem. A patient can look well, feel only intermittently unwell, and still carry a bacterium capable of altering the gastric mucosa for years.
Transmission most commonly occurs within families, through oral-oral or faecal-oral routes. In practical terms, household exposure matters because infection does not arise in isolation; it often moves along close-contact networks where shared living conditions, hygiene practices, and repeated exposure can sustain spread. That family-based pattern also helps explain why a single positive test can reflect more than an individual diagnosis. It can signal clustered infection within the same home.
Geographic prevalence shapes the threshold to test
Prevalence varies sharply by region, and those differences drive clinical decision-making. Infection rates are higher in low and middle income countries, where systematic review and meta-analysis data place prevalence at 40% to 60%, compared with about 30% in developed regions. In some countries in Africa, the Middle East, and the Americas, rates reach 60% to 80%. Asian and Western Pacific regions show moderate prevalence overall, but the spread is wide, ranging from 9.2% to 78.8% across settings.
The pattern is similar in North America, where prevalence ranges from 17.6% to 37.9%. In Europe, the average prevalence between 2010 and 2022 was 39.6% in adults and 29.1% in children. In the UK, those averages were lower, at 26.3% in adults and 7.4% in children. Those figures matter because they frame how often clinicians should expect to encounter infection and how much pre-test probability should influence evaluation. A low-prevalence setting changes the interpretation of symptoms, but it does not eliminate the need to consider the organism in persistent or recurrent dyspepsia, unexplained gastritis, or other compatible presentations.
Non-invasive testing is the front door to diagnosis
The most common investigations for H pylori are non-invasive tests, especially the urea breath test and the stool antigen test. Both are central to modern detection because they avoid endoscopy in many patients and fit naturally into primary care workflows. For symptomatic adults without alarm features or complicated disease, that approach is efficient and patient-centered. It also reduces delays that can occur when invasive testing is reserved too early or too broadly.
A straight path through diagnosis is important because the bacterium is not just a marker of inflammation; it is a treatable cause of disease. Once identified, the organism should not be treated as a background incidental finding. Eradication interrupts the biological process that sustains chronic gastritis and lowers downstream risk. In a patient with persistent dyspepsia, the diagnostic sequence is therefore not merely administrative. It determines whether the root cause is addressed or simply observed.
Family-based treatment changes the unit of care
International guidelines recommend offering treatment to all infected individuals. That broad recommendation reflects the organism’s role in chronic gastric injury and the potential to prevent later complications. A family-based treatment approach has also recently been introduced, which is especially relevant when transmission is concentrated within households. Treating one person while overlooking infected close contacts can leave the underlying chain intact.
The family model shifts the clinical frame from individual illness to shared exposure. It makes sense biologically because recurrent transmission inside the home can undermine eradication efforts and perpetuate infection in vulnerable members. It also fits the reality of H pylori as a condition often acquired early in life and maintained by close contact over time. When a household cluster is present, the question is not only who is symptomatic today, but who remains at risk of carrying or reacquiring the organism.
Primary care carries most of the workload
Many patients with H pylori infection are assessed and managed in primary care when there are no associated complications. That setting is where symptoms first surface, where non-invasive testing is often initiated, and where treatment decisions are most frequently made. Referral to gastroenterology becomes more common when disease is difficult to investigate or treat. That may include patients whose symptoms persist despite treatment, whose diagnostic picture remains unclear, or whose presentation suggests a more complicated gastric process.
The clinical update also places the infection in the context of international variation in guidance. Recommendations differ based on local prevalence and resistance patterns, which means a one-size-fits-all strategy is rarely appropriate. A region with high infection rates and distinct antibiotic resistance patterns may justify a different testing and treatment threshold than a low-prevalence setting. In practice, the clinician needs to match the test and the treatment plan to the local epidemiology rather than relying on a universal template.
A small but consequential point emerges here: asymptomatic infection is common. Silence does not equal harmlessness. Many patients will not volunteer symptoms, and some will only be found during evaluation for dyspepsia, family exposure, or broader gastrointestinal work-up. Once detected, the organism deserves active management because the aim is not only symptom relief, but interruption of chronic mucosal injury and reduction of longer-term gastric risk.
Why the infection still matters at the bedside
The bedside implications are straightforward even when the biology is not. H pylori remains prevalent, spreads within households, and is best detected with non-invasive tools in routine care. It produces gastritis in all infected individuals, but only a subset develop overt clinical disease, which can make the infection easy to miss unless clinicians keep a low threshold for testing in the right clinical context. International guidance favors treatment once infection is confirmed, and family-based management adds a broader preventive dimension when clustered transmission is likely.
What remains unresolved in daily practice is not whether the organism matters, but how best to apply guidance across settings where prevalence, access to testing, and resistance patterns differ. Those differences determine the real-world performance of detection and eradication strategies, and they shape how quickly primary care can move from suspicion to durable cure.